U.S. Communications Stock News

Boot Barn Holdings, Inc. ( NYSE:BOOT ) investors will be delighted, with the company turning in some strong numbers...

We wouldn't blame Blackbaud, Inc. ( NASDAQ:BLKB ) shareholders if they were a little worried about the fact that...

The analysts might have been a bit too bullish on Generac Holdings Inc. ( NYSE:GNRC ), given that the company fell...

Magnachip Semiconductor Corporation ( NYSE:MX ) shareholders won't be pleased to see that the share price has had a...

Anyone interested in Trustmark Corporation ( NASDAQ:TRMK ) should probably be aware that the Independent Director...

Some PriceSmart, Inc. ( NASDAQ:PSMT ) shareholders may be a little concerned to see that the President & COO, John...

When you see that almost half of the companies in the Oil and Gas industry in the United States have price-to-sales...

Investors who take an interest in Norwegian Cruise Line Holdings Ltd. ( NYSE:NCLH ) should definitely note that the...

To the annoyance of some shareholders, Art's-Way Manufacturing Co., Inc. ( NASDAQ:ARTW ) shares are down a considerable...

The analysts covering Kinetik Holdings Inc. ( NYSE:KNTK ) delivered a dose of negativity to shareholders today, by...

What financial metrics can indicate to us that a company is maturing or even in decline? A business that's potentially...

The Concentrix Corporation ( NASDAQ:CNXC ) share price has fared very poorly over the last month, falling by a...

Curious if Elanco Animal Health stock is a hidden gem or already priced for perfection? You are not alone. It may be worth taking a closer look at its current valuation story. While the stock dipped 3.0% over the last week, it has surged an impressive 78.3% year-to-date and 52.7% in the past year. This suggests shifting market sentiment and renewed optimism. Much of this momentum has been driven by enthusiasm around Elanco’s strategic moves in animal healthcare innovation and recent...

Limbach Holdings, Inc. recently reported strong third quarter 2025 results, with sales rising to US$184.58 million and net income increasing to US$8.79 million, while also reaffirming its full-year revenue guidance. An important insight is that the company’s focus on expanding owner-direct relationships and integrating the Pioneer Power acquisition has shifted over three-quarters of its revenue to recurring service contracts, supporting operational momentum and margin growth...

Ever wondered if Investar Holding is trading for less than it’s really worth? Let’s dig into what the numbers and market buzz reveal about its current value. The stock has climbed 3.4% over the past month and is up 11.9% since the start of the year, signaling renewed investor interest and possibly shifting sentiment around its growth prospects. Recently, the company completed a strategic acquisition aimed at expanding its regional presence, which has caught the eye of both analysts and...

In November 2025, Eledon Pharmaceuticals presented results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in kidney transplant recipients at the American Society of Nephrology's Kidney Week Annual Meeting. Although the primary endpoint did not meet statistical significance, the drug showed a promising safety profile and higher kidney function in some key patient subgroups compared to standard tacrolimus therapy. We'll explore how tegoprubart's...

Earlier this month, Clean Energy Fuels Corp. reported third-quarter 2025 earnings with revenue of US$106.1 million, exceeding analyst expectations, while announcing expanded renewable natural gas (RNG) production and several new supply agreements with major fleet operators and infrastructure clients nationwide. The company also secured contracts for hydrogen fueling stations and highlighted commissioning of dairy RNG projects, pointing to diversification and growth in decarbonization...

Hawkins, Inc. recently reported its second quarter and six-month results, with sales rising to US$280.43 million for the quarter, while net income and earnings per share declined compared to the previous year. The Board also declared a quarterly cash dividend of US$0.19 per share, emphasizing the company’s ongoing commitment to shareholder returns. We’ll examine how sustained sales growth alongside lower earnings shapes Hawkins’ current investment narrative for shareholders. Explore 27 top...

Akero Therapeutics (AKRO) stock has been quietly trending higher this month, gaining roughly 16% despite little in the way of major news. Many investors are revisiting the company’s progress and recent momentum. See our latest analysis for Akero Therapeutics. Akero’s impressive 16% share price return this month builds on a strong year, with momentum clearly gaining steam. The stock has surged 92.5% year-to-date. While recent news has been quiet, long-term total shareholder returns have also...

In recent news, Voyager Technologies raised its full-year 2025 sales guidance to the upper end of its US$165 million to US$170 million range, citing strong performance from recent acquisitions and substantial defense segment growth. This announcement underscores the company's focus on execution and expansion, exemplified by continued momentum in its government and commercial partnerships despite sector volatility. We will explore how Voyager Technologies' upgraded sales outlook and robust...

Gibraltar Industries reported third-quarter and nine-month 2025 results on October 30, showing higher sales year-over-year but shifting from net income to a US$89.06 million net loss for the quarter and a US$41.94 million net loss for the year to date. Despite increased revenues, the swing to losses and more cautious full-year earnings guidance highlighted underlying profitability challenges and raised questions about the sustainability of recent operational improvements. We'll now explore...

Wondering if Gambling.com Group is a golden opportunity trading below its fair value, or if the recent turbulence has put the stock in the bargain bin? Let’s take a closer look at what is really behind the current price. Shares have slipped by 6.7% over the last week and are down a hefty 54.6% year-to-date, highlighting how much sentiment and perceived risk can shift for this stock. Ongoing discussions surrounding digital gambling legislation and increased competition in the affiliate...

SunOpta Inc. recently reported improved third quarter results, turning a profit, and raised its revenue guidance for 2025 to US$812 million–US$816 million, while also providing a 2026 revenue outlook of US$865 million–US$880 million. This upward revision in guidance, combined with year-over-year sales growth and positive earnings, highlights strengthened operations and management’s confidence in future performance despite a third quarter impairment charge. We’ll assess how SunOpta’s...

Cidara Therapeutics recently announced progress in its Phase 3 ANCHOR study for CD388, securing a US$45 million milestone payment from Janssen, a BARDA award valued up to US$339.2 million to support manufacturing, and receiving FDA Breakthrough Therapy designation. These updates highlight the growing validation and financial support behind CD388, a promising immunotherapeutic candidate for influenza prevention and serious diseases. We'll explore how the combination of clinical and funding...